Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Pivotal Phase III trial of FG001 in Aggressive Brain Cancer

Next Previous
Trial Profile

A Pivotal Phase III trial of FG001 in Aggressive Brain Cancer

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 02 Dec 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs FG 001 (Primary)
  • Indications Glioblastoma; Glioma
  • Focus Registrational; Therapeutic Use
  • Sponsors FluoGuide

Most Recent Events

  • 27 Nov 2024 According to a FluoGuide media release, updates expected in the first half of next year.
  • 08 Jan 2024 According to a FluoGuide media release, the company plans to advance FG001 into the first clinical trial for registration of FG001 in fluorescence guided surgery (FGS) of aggressive brain cancer, based on feedback from the U.S. Food and Drug Administration (FDA).
  • 08 Jan 2024 According to a FluoGuide media release, Clinical trial to be used for registration of FG001 in fluorescent guided surgery of aggressive brain cancer expected to start in 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top